| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3760 |
| Trial ID | NCT06256484 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ATA3219 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
| Year | 2024 |
| Country | United States |
| Company sponsor | Atara Biotherapeutics |
| Other ID(s) | ATA3219-NHL-103 |
| Cohort 1 | |||||||||
|
|||||||||